Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know
Fierce Pharma
Wed, 07/12/23 - 11:03 pm
Eisai
Biogen
Leqembi
drug pricing
Medicare
Alzheimer's disease
Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker
Fierce Biotech
Fri, 07/7/23 - 08:40 am
BrainStorm Cell Therapeutics
ALS
cell therapy
Biogen
NurOwn
Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s
BioSpace
Thu, 07/6/23 - 10:08 pm
Biogen
Eisai
Leqembi
FDA
Alzheimer's disease
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
Biogen shareholders vote in Susan Langer as director despite relationship with former board member
Fierce Pharma
Mon, 06/26/23 - 08:42 pm
Biogen
shareholders
5 FDA decisions to watch in the third quarter
BioPharma Dive
Mon, 06/26/23 - 10:04 am
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
Motley Fool
Fri, 06/23/23 - 10:03 am
Biogen
Eisai
Alzheimer's disease
FDA
Leqembi
Roche drops antisense drug after seeing efficacy data, leaving Biogen, Ionis and Ultragenyx to duke it out
Fierce Biotech
Fri, 06/23/23 - 09:46 am
Roche
Angelman Syndrome
antisense
Biogen
Ionis Pharmaceuticals
Ultragenyx
rugonersen
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Motley Fool
Mon, 06/19/23 - 10:21 am
Eisai
Biogen
Leqembi
Alzheimer's disease
Europe
On the Cusp of Full Approval, Leqembi’s Rollout Could Face Challenges
BioSpace
Fri, 06/16/23 - 10:01 am
Eisai
Biogen
Alzheimer's disease
FDA
Leqembi
The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules
Forbes
Wed, 06/14/23 - 06:42 pm
Alzheimer's disease
drug pricing
Medicare
Biogen
Eisai
Leqembi
Biogen teams with NeuroSense to explore ALS neurofilament biomarker
BioSpace
Wed, 06/14/23 - 11:35 am
Biogen
NeuroSense Therapeutics
ALS
PrimeC
Biogen Makes Changes to Board of Directors Ahead of Annual Shareholder Meeting
BioSpace
Tue, 06/13/23 - 10:44 am
Biogen
How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial
Forbes
Mon, 06/12/23 - 10:08 am
clinical trials
innovation
ALS
Parkinson's Disease
Biogen
FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug
BioPharma Dive
Sun, 06/11/23 - 11:14 pm
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
Eisai files Leqembi in Korea, as US prospects firm up
Pharmaphorum
Thu, 06/8/23 - 10:02 am
Eisai
Biogen
Leqembi
Alzheimer's disease
South Korea
Asia
Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 06/7/23 - 09:53 pm
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Wed, 06/7/23 - 09:34 pm
Alzheimer's disease
FDA
insurance
Leqembia
Biogen
Eisai
Eli Lilly
donanemab
After Merck's flashpoint IRA lawsuit, Biogen CEO and others register their own complaints
Fierce Biotech
Wed, 06/7/23 - 10:15 am
Merck
Inflation Reduction Act
legal
drug pricing
Biogen
Novartis
Genentech
BIO 2023
FDA Removes Expert with Ties to Eisai, Biogen from Leqembi Adcomm
BioSpace
Tue, 06/6/23 - 10:17 am
FDA
Biogen
Eisai
Alzheimer's disease
Leqembi
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »